Literature DB >> 15025473

A wrench-shaped synthetic molecule that modulates a transcription factor-coactivator interaction.

Hiroki Shimogawa1, Youngjoo Kwon, Qian Mao, Yoshinori Kawazoe, Yongmun Choi, Shinichi Asada, Hideo Kigoshi, Motonari Uesugi.   

Abstract

Development of synthetic molecules that provide external control over the transcription of a given gene represents a challenge in medicinal and bioorganic chemistry. Here we report design and analysis of wrenchnolol, a wrench-shaped synthetic molecule that impairs the transcription of the Her2 oncogene by disrupting association of transcription factor ESX with its coactivator Sur-2. The "jaw" part of the compound mimics the alpha-helical interface of the activation domain of ESX, and the "handle" region accepts chemical modifications for a range of analysis. A water-soluble handle permitted NMR study in aqueous solution; a biotinylated handle verified the selectivity of the interaction, and a fluorescent handle confirmed the cell permeability of the compound. The case study of wrenchnolol foreshadows the promise and the challenge of targeting protein-protein interactions in the nucleus and may lead to the development of unique synthetic modulators of gene transcription.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15025473     DOI: 10.1021/ja038855+

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  14 in total

Review 1.  The mediator of RNA polymerase II.

Authors:  Erik Blazek; Gerhard Mittler; Michael Meisterernst
Journal:  Chromosoma       Date:  2005-02-03       Impact factor: 4.316

Review 2.  Transcriptional switches: chemical approaches to gene regulation.

Authors:  Lori W Lee; Anna K Mapp
Journal:  J Biol Chem       Date:  2010-02-10       Impact factor: 5.157

Review 3.  Small-molecule regulators that mimic transcription factors.

Authors:  José A Rodríguez-Martínez; Kimberly J Peterson-Kaufman; Aseem Z Ansari
Journal:  Biochim Biophys Acta       Date:  2010-09-06

4.  Inhibition of ErbB2(Her2) expression with small molecule transcription factor mimics.

Authors:  Lori W Lee; Christopher E C Taylor; Jean-Paul Desaulniers; Manchao Zhang; Jonas W Højfeldt; Quintin Pan; Anna K Mapp
Journal:  Bioorg Med Chem Lett       Date:  2009-09-01       Impact factor: 2.823

5.  Effective Procedure for Selective Ammonolysis of Monosubstituted Oxiranes: Application to E7389 Synthesis.

Authors:  Yosuke Kaburagi; Yoshito Kishi
Journal:  Tetrahedron Lett       Date:  2007-12       Impact factor: 2.415

6.  Sekikaic acid and lobaric acid target a dynamic interface of the coactivator CBP/p300.

Authors:  Chinmay Y Majmudar; Jonas W Højfeldt; Carl J Arevang; William C Pomerantz; Jessica K Gagnon; Pamela J Schultz; Laura C Cesa; Conor H Doss; Steven P Rowe; Victor Vásquez; Giselle Tamayo-Castillo; Tomasz Cierpicki; Charles L Brooks; David H Sherman; Anna K Mapp
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-08       Impact factor: 15.336

Review 7.  Reprogramming cell fate with artificial transcription factors.

Authors:  Evan A Heiderscheit; Asuka Eguchi; Mackenzie C Spurgat; Aseem Z Ansari
Journal:  FEBS Lett       Date:  2018-02-11       Impact factor: 4.124

8.  Design and synthesis of a cell-permeable synthetic transcription factor mimic.

Authors:  Xiangshu Xiao; Peng Yu; Hyun-Suk Lim; Devanjan Sikder; Thomas Kodadek
Journal:  J Comb Chem       Date:  2007-05-27

9.  Inhibition of hypoxia inducible factor 1-transcription coactivator interaction by a hydrogen bond surrogate alpha-helix.

Authors:  Laura K Henchey; Swati Kushal; Ramin Dubey; Ross N Chapman; Bogdan Z Olenyuk; Paramjit S Arora
Journal:  J Am Chem Soc       Date:  2010-01-27       Impact factor: 15.419

10.  Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.

Authors:  Manchao Zhang; Christopher E Taylor; Longzhu Piao; Jharna Datta; Paul A Bruno; Sanjay Bhave; Tizhi Su; James C Lang; Xiujie Xie; Theodoros N Teknos; Anna K Mapp; Quintin Pan
Journal:  Mol Cancer Ther       Date:  2013-05-30       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.